According to a recent LinkedIn post from RyboDyn Inc, the company is bringing on Michele Bronson, Ph.D., as a Strategic Scientific & Clinical Advisor. The post highlights her more than 20 years of biotech experience and involvement in eight drug approvals across oncology, immunology, neurology, and rare diseases.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post notes Bronson’s background leading global development from pre-IND through approval and her work on therapies such as enzalutamide (Xtandi) and fremanezumab (Ajovy). It also indicates that she has overseen development operations for multiple first-in-class therapies and built teams to translate early-stage science into approved medicines.
RyboDyn’s post suggests this appointment is intended to bolster clinical, regulatory, and operational execution as it advances its Cryptic Targets™ platform toward clinical development. For investors, the addition of an advisor with late-stage and regulatory experience may reduce execution risk, potentially improving the company’s prospects for progressing assets and partnering or financing in a competitive biotech landscape.